Study detail
RecruitingPhase 3
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
Henry Ford Health System
Summary
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Eligibility
- Age range
- 18–80 years
- Sex
- All
- Healthy volunteers
- No
Detailed criteria
Inclusion Criteria: * • Patients 18-80 years of age with a diagnosis of a hematological malignancy * Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies Exclusion Criteria: * • Patients enrolled in investigational clinical trials * Sct for non hematologic malignancies
Interventions
- DrugBudesonide
budesonide starting day 5 after transplant
Location
- Henry Ford Health SystemDetroit, Michigan